Evaluation of urinary ribonucleoside profiling for clinical biomarker discovery using constant neutral loss scanning liquid chromatography/tandem mass spectrometry

Rapid Communications in Mass Spectrometry

Volumn 25, Issue 14, 2011, Pages 2071-2082

  Teichert, Friederike ^a   Winkler, Swantje ^a   Keun, Hector C ^b   Steward, William P ^a   Gescher, Andreas J ^a   Farmer, Peter B ^a   Singh, Rajinder ^a  

^a UNIVERSITY OF LEICESTER   (United Kingdom)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BODY FLUIDS; CLINICAL RESEARCH; DIGITAL STORAGE; LIQUID CHROMATOGRAPHY; MASS SPECTROMETERS; MASS SPECTROMETRY;

BIO-MARKER DISCOVERY; CLINICAL BIOMARKERS; DIURNAL VARIATION; INTER-DAY VARIATIONS; LIQUID CHROMATOGRAPHY-TANDEM MASS SPECTROMETRY; LIQUID CHROMATOGRAPHY/TANDEM MASS SPECTROMETRY; NEUTRAL LOSS SCANNING; RIBONUCLEOSIDES; SAMPLE PREPARATION; URINE SAMPLE;

BIOMARKERS;

EID: 79959638816     PISSN: 09514198     EISSN: 10970231     Source Type: Journal    
DOI: 10.1002/rcm.5086     Document Type: Article

References (59)

1. G. Sander, H. Topp, J. Wieland, G. Heller-Schoch, G. Schoch,. Possible use of urinary modified RNA metabolites in the measurement of RNA turnover in the human body. Hum. Nutr. Clin. Nutr. 1986, 40, 103.
2. C. C. Marvel, J. Del Rowe, E. G. Bremer, J. R. Moskal,. Altered RNA turnover in carcinogenesis: the diagnostic potential of modified base excretion. Mol. Chem. Neuropathol. 1994, 21, 353.
3. K. Nakano, T. Nakao, K. H. Schram, W. M. Hammargren, T. D. McClure, M. Katz, E. Petersen,. Urinary excretion of modifed nucleosides as biological marker of RNA turnover in patients with cancer and AIDS. Clin. Chim. Acta 1993, 218, 169.
4. A. Fischbein, O. K. Sharma, I. J. Selikoff, E. Borek,. Urinary excretion of modified nucleosides in patients with malignant mesothelioma. Cancer Res. 1983, 43, 2971.
5. K. H. Schram,. Urinary nucleosides. Mass Spectrom. Rev. 1998, 17, 131.
6. A. Seidel, S. Brunner, P. Seidel, G. I. Fritz, O. Herbarth,. Modified nucleosides: An accurate tumour marker for clinical diagnosis of cancer, early detection and therapy control. Br. J. Cancer 2006, 94, 1726.
7. P. A. Limbach, P. F. Crain, J. A. McCloskey,. Summary: the modified nucleosides of RNA. Nucleic Acids Res. 1994, 22, 2183.
8. L. R. Mandel, P. R. Srinivasan, E. Borek,. Origin of urinary methylated purines. Nature 1966, 209, 586.
9. M. J. Moore,. Nuclear RNA turnover. Cell 2002, 108, 431.
10. J. Houseley, D. Tollervey,. The many pathways of RNA degradation. Cell 2009, 136, 763.
11. D. B. Lakings, T. P. Waalkes, E. Borek, C. W. Gehrke, J. E. Mrochek, J. Longmore, R. H. Adamson,. Composition, associated tissue methyltransferase activity, and catabolic end products of transfer RNA from carcinogen induced hepatoma and normal monkey livers. Cancer Res. 1977, 37, 285.
12. W. Z. Wang, X. J. Zhao, X. Li, J. Chen, F. L. Li, G. W. Xu,. Lung cancer diagnosis based on urinary modified nucleoside metabolic profiling. Acta Acad. Med. Sin. 2007, 29, 738.
13. T. P. Waalkes, M. D. Abeloff, D. S. Ettinger,. Modified ribonucleosides as biological markers for patients with small cell carcinoma of the lung. Eur. J. Cancer Clin. Oncol. 1982, 18, 1267.
14. J. Yang, G. Xu, Y. Zheng, H. Kong, T. Pang, S. Lv, Q. Yang,. Diagnosis of liver cancer using HPLC-based metabonomics avoiding false-positive result from hepatitis and hepatocirrhosis diseases. J. Chromatogr. B 2004, 813, 59.
15. L. B. Jeng, W. Y. Lo, W. Y. Hsu, W. D. Lin, C. T. Lin, C. C. Lai, F. J. Tsai,. Analysis of urinary nucleosides as helper tumor markers in hepatocellular carcinoma diagnosis. Rapid Commun. Mass Spectrom. 2009, 23, 1543.
16. A. J. Sasco, F. Rey, C. Reynaud, J. Y. Bobin, M. Clavel, A. Niveleau,. Breast cancer prognostic significance of some modified urinary nucleosides. Cancer Lett. 1996, 108, 157.
17. Y. F. Zheng, H. W. Kong, J. H. Xiong, S. Lv, G. W. Xu,. Clinical significance and prognostic value of urinary nucleosides in breast cancer patients. Clin. Biochem. 2005, 38, 24.
18. A. Frickenschmidt, H. Fröhlich, D. Bullinger, A. Zell, S. Laufer, C. H. Gleiter, H. Liebich, B. Kammerer,. Metabonomics in cancer diagnosis: Mass spectrometry-based profiling of urinary nucleosides from breast cancer patients. Biomarkers 2008, 13, 435.
19. G. Xu, H. R. Schmid, X. Lu, H. M. Liebich, P. Lu,. Excretion pattern investigation of urinary normal and modified nucleosides of breast cancer patients by RP-HPLC and factor analysis method. Biomed. Chromatogr. 2000, 14, 459.
20. E. Kvist, K. E. Sjolin, J. Iversen, K. Nyholm,. Urinary excretion patterns of pseudouridine and β-aminoisobutyric acid in patients with tumours of the urinary bladder. Scand. J. Urol. Nephrol. 1993, 27, 45.
21. Y. F. Zheng, J. Yang, X. J. Zhao, B. Feng, H. W. Kong, Y. J. Chen, S. Lv, M. H. Zheng, G. W. Xu,. Urinary nucleosides as biological markers for patients with colorectal cancer. World J. Gastroenterol. 2005, 11, 3871.
22. B. Feng, M. H. Zheng, Y. F. Zheng, A. G. Lu, J. W. Li, M. L. Wang, J. J. Ma, G. W. Xu, B. Y. Liu, Z. G. Zhu,. Normal and modified urinary nucleosides represent novel biomarkers for colorectal cancer diagnosis and surgery monitoring. J. Gastroenterol. Hepatol. 2005, 20, 1913.
23. W. Y. Hsu, W. T. L. Chen, W. D. Lin, F. J. Tsai, Y. Tsai, C. T. Lin, W. Y. Lo, L. B. Jeng, C. C. Lai,. Analysis of urinary nucleosides as potential tumor markers in human colorectal cancer by high performance liquid chromatography/electrospray ionization tandem mass spectrometry. Clin. Chim. Acta 2009, 402, 31.
24. S. La, J. Cho, J. H. Kim, K. R. Kim,. Capillary electrophoretic profiling and pattern recognition analysis of urinary nucleosides from thyroid cancer patients. Anal. Chim. Acta 2003, 486, 171.
25. F. Oerlemans, F. Lange,. Major and modified nucleosides as markers in ovarian cancer: A pilot study. Gynecol. Obstet. Invest. 1986, 22, 212.
26. T. Rasmuson, G. R. Bjork,. Urinary excretion of pseudouridine and prognosis of patients with malignant lymphoma. Acta Oncol. 1995, 34, 61.
27. K. Itoh, T. Konno, T. Sasaki, S. Ishiwata, N. Ishida, M. Misugaki,. Relationship of urinary pseudouridine and 1-methyladenosine to activity of leukemia and lymphoma. Clin. Chim. Acta 1992, 206, 181.
28. J. Thomale, A. Luz, G. Nass,. Excretion of modified nucleosides during development of malignant lymphomas in mice after whole body irradiation. J. Cancer Res. Clin. Oncol. 1984, 108, 302.
29. J. A. Ludwig, J. N. Weinstein,. Biomarkers in cancer staging, prognosis and treatment selection. Nat. Rev. Cancer 2005, 5, 845.
30. S. Gutman, L. G. Kessler,. Opinion: The US Food and Drug Administration perspective on cancer biomarker development. Nat. Rev. Cancer 2006, 6, 565.
31. R. Etzioni, N. Urban, S. Ramsey, M. McIntosh, S. Schwartz, B. Reid, J. Radich, G. Anderson, L. Hartwell,. The case for early detection. Nat. Rev. Cancer 2003, 3, 243.
32. H. M. Liebich, G. Xu, C. Di Stefano, R. Lehmann,. Capillary electrophoresis of urinary normal and modified nucleosides of cancer patients. J. Chromatogr. A 1998, 793, 341.
33. H. M. Liebich, R. Lehmann, G. Xu, H. G. Wahl, H. U. Häring,. Application of capillary electrophoresis in clinical chemistry: The clinical value of urinary modified nucleosides. J. Chromatogr. B 2000, 745, 189.
34. Y. Jiang, Y. Ma,. A fast capillary electrophoresis method for separation and quantification of modified nucleosides in urinary samples. Anal. Chem. 2009, 81, 6474.
35. M. J. Markuszewski, W. Struck, M. Waszczuk-Jankowska, R. Kaliszan,. Metabolomic approach for determination of urinary nucleosides as potential tumor markers using electromigration techniques. Electrophoresis 2010, 31, 2300.
36. K. Nakano, K. Shindo, T. Yasaka,. Reversed-phase high-performance liquid chromatographic investigation of mucosal nucleosides and bases and urinary modified nucleosides of gastrointestinal cancer patients. J. Chromatogr. 1985, 343, 21.
37. G. E. Davis, R. D. Suits, K. C. Kuo, C. W. Gehrke, T. P. Waalkes, E. Borek,. High performance liquid chromatographic separation and quantitation of nucleosides in urine and some other biological fluids. Clin. Chem. 1977, 23, 1427.
38. H. M. Liebich, C. Di Stefano, A. Wixforth, H. R. Schmid,. Quantitation of urinary nucleosides by high-performance liquid chromatography. J. Chromatogr. A 1997, 763, 193.
39. G. Xu, C. Di Stefano, H. M. Liebich, Y. Zhang, P. Lu,. Reversed-phase high-performance liquid chromatographic investigation of urinary normal and modified nucleosides of cancer patients. J. Chromatogr. B 1999, 732, 307.
40. S. Ishiwata, K. Itoh, T. Yamaguchi, N. Ishida, M. Mizugaki,. Comparison of serum and urinary levels of modified nucleoside, 1-methyladenosine, in cancer patients using a monoclonal antibody-based inhibition ELISA. Tohoku J. Exp. Med. 1995, 176, 61.
41. J. S. Marway, G. J. Anderson, J. P. Miell, R. Ross, G. K. Grimble, A. B. Bonner, W. A. Gibbons, T. J. Peters, V. R. Preedy,. Application of proton NMR spectroscopy to measurement of whole-body RNA degradation rates: Effects of surgical stress in human patients. Clin. Chim. Acta 1996, 252, 123.
42. J. I. Langridge, T. D. McClure, S. El-Shakawi, A. Fielding, K. H. Schram, R. P. Newton,. Gas chromatography/mass spectrometric analysis of urinary nucleosides in cancer patients; potential of modified nucleosides as tumour markers. Rapid Commun. Mass Spectrom. 1993, 7, 427.
43. D. Bullinger, A. Frickenschmidt, M. Pelzing, T. Zey, G. Zurek, S. Laufer, B. Kammerer,. Identification of urinary nucleosides by ESI-TOF-MS. LC-GC Eur. 2005, 18, 16.
44. B. Kammerer, A. Frickenschmidt, C. H. Gleiter, S. Laufer, H. Liebich,. MALDI-TOF MS analysis of urinary nucleosides. J. Am. Soc. Mass Spectrom. 2005, 16, 940.
45. A. Bond, E. Dudley, F. Lemière, R. Tuytten, S. El-Sharkawi, A. G. Brenton, E. L. Esmans, R. P. Newton,. Analysis of urinary nucleosides. V. Identification of urinary pyrimidine nucleosides by liquid chromatography/ electrospray mass spectrometry. Rapid Commun. Mass Spectrom. 2006, 20, 137.
46. R. Singh, P. B. Farmer,. Liquid chromatography-electrospray ionization-mass spectrometry: The future of DNA adduct detection. Carcinogenesis 2006, 27, 178.
47. D. Bullinger, R. Fux, G. Nicholson, S. Plontke, C. Belka, S. Laufer, C. H. Gleiter, B. Kammerer,. Identification of urinary modified nucleosides and ribosylated metabolites in humans via combined ESI-FTICR MS and ESI-IT MS analysis. J. Am. Soc. Mass Spectrom. 2008, 19, 1500.
48. R. Tuytten, F. Lemière, W. Van Dongen, E. Witters, E. L. Esmans, R. P. Newton, E. Dudley,. Development of an on-line SPE-LC-ESI-MS method for urinary nucleosides: Hyphenation of aprotic boronic acid chromatography with hydrophilic interaction LC-ESI-MS. Anal. Chem. 2008, 80, 1263.
49. H. Y. Li, S. M. Wang, H. M. Liu, S. S. Bu, J. Li, D. Han, M. Z. Zhang, G. Y. Wu,. Separation and identification of purine nucleosides in the urine of patients with malignant cancer by reverse phase liquid chromatography/ electrospray tandem mass spectrometry. J. Mass Spectrom. 2009, 44, 641.
50. E. Dudley, S. El-Sharkawi, D. E. Games, R. P. Newton,. Analysis of urinary nucleosides. I. Optimisation of high performance liquid chromatography/electrospray mass spectrometry. Rapid Commun. Mass Spectrom. 2000, 14, 1200.
51. D. Bullinger, H. Neubauer, T. Fehm, S. Laufer, C. H. Gleiter, B. Kammerer,. Metabolic signature of breast cancer cell line MCF-7: Profiling of modified nucleosides via LC-IT MS coupling. BMC Biochem. 2007, 8, 25.
52. 1H NMR spectroscopy-based metabolic phenotyping studies. Anal. Chem. 2007, 79, 5204.
53. H. Topp, G. Schöch,. Whole-body degradation rates of transfer-, ribosomal-, and messenger ribonucleic acids and resting metabolic rate in 3- to 18-year-old humans. Pediatr. Res. 2000, 47, 163.
54. H. Topp, S. Unverzagt, S. Rudloff, G. Schöch, F. Manz, C. Fusch,. Diurnal variation in the renal excretion of modified RNA catabolites in humans. Clin. Sci. 2003, 105, 195.
55. C. Henneges, D. Bullinger, R. Fux, N. Friese, H. Seeger, H. Neubauer, S. Laufer, C. H. Gleiter, M. Schwab, A. Zell, B. Kammerer,. Prediction of breast cancer by profiling of urinary RNA metabolites using Support Vector Machine-based feature selection. BMC Cancer 2009, 9, 104.
56. C. A. Smith, E. J. Want, G. O'Maille, R. Abagyan, G. Siuzdak,. XCMS: Processing mass spectrometry data for metabolite profiling using nonlinear peak alignment, matching, and identification. Anal. Chem. 2006, 78, 779.
57. T. Pluskal, S. Castillo, A. Villar-Briones, M. Orešič,. MZmine 2: Modular framework for processing, visualizing, and analyzing mass spectrometry-based molecular profile data. BMC Bioinformatics. 2010, 11, 395.
58. E. Szymanska, M. J. Markuszewski, K. Bodzioch, R. Kaliszan,. Development and validation of urinary nucleosides and creatinine assay by capillary electrophoresis with solid phase extraction. J. Pharm. Biomed. Anal. 2007, 44, 1118.
59. R. Tuytten, F. Lemière, E. L. Esmans, W. A. Herrebout, B. J. Van Der Veken, B. U. W. Maes, E. Witters, R. P. Newton, E. Dudley,. Role of nitrogen Lewis basicity in boronate affinity chromatography of nucleosides. Anal. Chem. 2007, 79, 6662.